

13 January 2022

## Cancer Treatments

**In the past 3 months, how many Urothelial Cancer patients were treated with the below:**

*Please Note: Urothelial Cancers are coded under Bladder in RISOH so this data includes all Bladder patients.*

- a) **Atezolizumab** 26
- b) **Carboplatin with Gemcitabine** 25
- c) **Carboplatin single or in any other combination** less than 5
- d) **Cisplatin with Gemcitabine** 33
- e) **Cisplatin single or in any other combination** 0
- f) **Nivolumab** 0
- g) **Pembrolizumab** less than 5
- h) **Any other regimen including Paclitaxel** 0
- i) **Any other chemotherapy regimen** 0
- j) **Other active systemic anti-cancer therapy (please state) Avelumab** 5
- k) **Palliative care only** Not available via our recording system

**Does your Trust participate in any ongoing clinical trials for the treatment of Urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?**

Trial detail requested are below:

**MK3475-045:** A Phase III Randomised Clinical Trial of MK-3475 versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer. This study has now closed to recruitment having recruited less than 5 patients. Some patients continue on follow up in the extension study: **MK3475-587** A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

The following two studies are currently in set-up:

**IMvigor011:** A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH RISK MUSCLE INVASIVE BLADDER CANCER WHO ARE CTDNA-POSITIVE FOLLOWING CYSTECTOMY

**RE-ARM:** A Randomised phase II trial of Enhancement of efficacy of Atezolizumab by Radiotherapy in Metastatic urothelial carcinoma